| scholarly article | Q13442814 |
| P2093 | author name string | Ryan A Wilcox | |
| P2860 | cites work | Simplified flow cytometric assessment in mycosis fungoides and Sézary syndrome | Q82563451 |
| Mycosis fungoides in the pediatric population: report from an international Childhood Registry of Cutaneous Lymphoma | Q82768247 | ||
| Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma | Q83002044 | ||
| FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome | Q84278927 | ||
| Dosing of a phase I study of KW-0761, an anti-CCR4 antibody, for adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma | Q84451076 | ||
| Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides | Q84566867 | ||
| IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases | Q84667105 | ||
| Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy | Q85841955 | ||
| Mogamulizumab: 2 birds, 1 stone | Q86963519 | ||
| Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15 | Q80489712 | ||
| Tissue microarray-based screening for chromosomal breakpoints affecting the T-cell receptor gene loci in mature T-cell lymphomas | Q80507534 | ||
| Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome | Q81294203 | ||
| Comparative genomic hybridization identifies 17q11.2 approximately q12 duplication as an early event in cutaneous T-cell lymphomas | Q81465967 | ||
| Utility of CD26 in flow cytometric immunophenotyping of T-cell lymphomas in tissue and body fluid specimens | Q81827357 | ||
| Multicolor fluorescence in situ hybridization (SKY) in mycosis fungoides and Sézary syndrome: search for recurrent chromosome abnormalities | Q82108645 | ||
| Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes. | Q51724214 | ||
| The vast majority of CLA+ T cells are resident in normal skin. | Q51984006 | ||
| Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. | Q52054622 | ||
| Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. | Q52059059 | ||
| Early TCR-beta and TCR-gamma PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications. | Q52942408 | ||
| Molecular analysis of T-cell receptor beta genes in cutaneous T-cell lymphoma reveals Jbeta1 bias. | Q53004728 | ||
| Absolute lymphocyte count predicts overall survival in follicular lymphomas. | Q53251809 | ||
| Monoclonal T-cell dyscrasia of undetermined significance associated with recalcitrant erythroderma. | Q53359615 | ||
| A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome. | Q53384690 | ||
| Clinical features associated with transformation of cerebriform T-cell lymphoma to a large cell process. | Q53506701 | ||
| Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. | Q53548352 | ||
| Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-Cell lymphomas suggesting impaired cell cycle control in disease pathogenesis. | Q53627567 | ||
| Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. | Q53635286 | ||
| Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. | Q54513502 | ||
| The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers. | Q54537315 | ||
| Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides. | Q54582099 | ||
| T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histolog | Q54647120 | ||
| Familial mycosis fungoides: report of 6 kindreds and a study of the HLA system. | Q54676191 | ||
| CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. | Q54695363 | ||
| Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells | Q56903036 | ||
| Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients | Q57009969 | ||
| Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells | Q57279527 | ||
| Occupational Sun Exposure and Mycosis Fungoides: A European Multicenter Case???Control Study | Q57563609 | ||
| Surface antigens on malignant Sézary and T-CLL cells correspond to those of mature T cells | Q57599636 | ||
| Detection of a Peripheral Blood T Cell Clone is an Independent Prognostic Marker in Mycosis Fungoides | Q57624829 | ||
| Phase II trial of interferon-?-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma | Q60685431 | ||
| Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma | Q60976795 | ||
| Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma | Q61833759 | ||
| Mycosis fungoides. Survival, prognostic features, response to therapy, and autopsy findings | Q67278867 | ||
| Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy | Q67557816 | ||
| Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome | Q67594854 | ||
| Mycosis fungoides--type cutaneous T-cell lymphoma arising before 30 years of age. Immunophenotypic, immunogenotypic and clinicopathologic analysis of nine cases | Q67982618 | ||
| Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice? | Q68030159 | ||
| The ultrastructure of an abnormal cell in Sézary's syndrome | Q68413447 | ||
| Ultrastructure of abnormal cells in Sezary syndrome, mycosis fungoides, and parapsoriasis en plaque | Q68475394 | ||
| Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma | Q68632118 | ||
| Interferon alfa-2a in the treatment of cutaneous T cell lymphoma | Q69735852 | ||
| A histologic study of lymph nodes from patients with the Sézary syndrome | Q69992670 | ||
| Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas | Q70224653 | ||
| Candidate counterparts of Sézary cells and adult T-cell lymphoma-leukaemia cells in normal peripheral blood: an ultrastructural study with the immunogold method and monoclonal antibodies | Q71001264 | ||
| Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders | Q71019976 | ||
| Combined modality therapy for cutaneous T-cell lymphoma | Q71120115 | ||
| Dermatopathic lymphadenopathy and lymph node involvement in mycosis fungoides | Q71128945 | ||
| Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry | Q71248580 | ||
| HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma | Q71381368 | ||
| Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses | Q71477713 | ||
| Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy | Q71868434 | ||
| Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy | Q71874205 | ||
| Immunophenotypic identification of Sezary cells in peripheral blood | Q71938114 | ||
| Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications | Q37512907 | ||
| Clinical studies of histone deacetylase inhibitors. | Q37512917 | ||
| Skin-resident T cells: the ups and downs of on site immunity | Q37579039 | ||
| High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. | Q37635287 | ||
| Current and emerging treatment strategies for cutaneous T-cell lymphoma | Q37694527 | ||
| Pralatrexate: basic understanding and clinical development | Q37761372 | ||
| Cancer-associated myeloproliferation: old association, new therapeutic target | Q37769017 | ||
| Histone deacetylase inhibitors in the treatment of lymphoma | Q37814536 | ||
| Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome. | Q37929548 | ||
| Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management | Q37944565 | ||
| Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: a systematic review | Q38028137 | ||
| U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma | Q38042090 | ||
| STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes | Q38311269 | ||
| Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells | Q38323614 | ||
| Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome | Q38463964 | ||
| A three-signal model of T-cell lymphoma pathogenesis | Q38593164 | ||
| PLCG1 mutations in cutaneous T-cell lymphomas | Q39027098 | ||
| Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma. | Q39506116 | ||
| Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma | Q39617721 | ||
| STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL. | Q39730561 | ||
| Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance | Q39744464 | ||
| Report of the Committee on Pathology of Cutaneous T Cell Lymphomas | Q39795737 | ||
| Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma | Q39883430 | ||
| Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation | Q39928789 | ||
| High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma | Q39933137 | ||
| Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma | Q39981886 | ||
| Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells | Q40012160 | ||
| Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents | Q40017228 | ||
| Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma | Q40070617 | ||
| Regulation of the HIF-1alpha stability by histone deacetylases | Q40175660 | ||
| Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in sezary syndrome patients | Q40340093 | ||
| Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma | Q40341141 | ||
| Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action | Q40349894 | ||
| Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. | Q40362906 | ||
| Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity | Q40401113 | ||
| Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. | Q40473507 | ||
| Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome | Q40566975 | ||
| The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. | Q40567775 | ||
| Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies | Q40623388 | ||
| Pentostatin therapy of T-cell lymphomas with cutaneous manifestations | Q40632049 | ||
| Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sézary syndrome | Q40637906 | ||
| A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides | Q40768413 | ||
| Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis | Q40833205 | ||
| Interferon in the treatment of cutaneous T-cell lymphoma | Q40923577 | ||
| Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients | Q40970585 | ||
| Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. | Q41071715 | ||
| Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Stud | Q41086530 | ||
| Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution | Q41262862 | ||
| Mycosis fungoides in relation to environmental exposures and immune response: a case-control study | Q41327858 | ||
| Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab | Q41591884 | ||
| PCR-heteroduplex analysis of T-cell receptor gamma gene rearrangement in paraffin-embedded skin biopsies | Q41756642 | ||
| Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease | Q41998297 | ||
| Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells | Q42156460 | ||
| The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. | Q42163084 | ||
| Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells | Q23909995 | ||
| Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73 | Q24302209 | ||
| Acetylation is indispensable for p53 activation | Q24313477 | ||
| Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation | Q24649964 | ||
| Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) | Q24681480 | ||
| Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management | Q27024076 | ||
| The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma | Q27824784 | ||
| Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome | Q28204642 | ||
| CCL27-CCR10 interactions regulate T cell-mediated skin inflammation | Q28217086 | ||
| Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sézary syndrome | Q28236693 | ||
| Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results | Q28300282 | ||
| The optimal use of bexarotene in cutaneous T-cell lymphoma | Q28305252 | ||
| Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy | Q30477329 | ||
| Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature | Q30650570 | ||
| Induction of MAGE-3 expression in lung and esophageal cancer cells | Q32054392 | ||
| Are alcohol intake and smoking associated with mycosis fungoides? A European multicentre case-control study | Q32142148 | ||
| Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma | Q33375600 | ||
| Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma | Q33376304 | ||
| Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma | Q33386623 | ||
| Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma | Q33387258 | ||
| Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study | Q33393701 | ||
| Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma | Q33400117 | ||
| A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma | Q33418737 | ||
| Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients | Q33505113 | ||
| GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features | Q33585286 | ||
| Prognostic factor analysis in mycosis fungoides/Sézary syndrome | Q33655920 | ||
| HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy | Q33778769 | ||
| Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma | Q33783663 | ||
| Oncogenic activation of NF-kappaB. | Q33849388 | ||
| Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation | Q33863049 | ||
| Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas | Q33873334 | ||
| Tumor-associated macrophages and survival in classic Hodgkin's lymphoma | Q33962334 | ||
| Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors | Q34052608 | ||
| Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling | Q34110250 | ||
| WHO-EORTC classification for cutaneous lymphomas | Q34391006 | ||
| Defining early mycosis fungoides. | Q34470437 | ||
| Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas | Q34470582 | ||
| Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood | Q34515597 | ||
| Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). | Q34520098 | ||
| Single agent and combination studies of pralatrexate and molecular correlates of sensitivity | Q34543815 | ||
| Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment | Q34633209 | ||
| High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma. | Q34667769 | ||
| The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. | Q34672100 | ||
| Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL. | Q34802998 | ||
| Guidelines on the use of extracorporeal photopheresis | Q34918643 | ||
| How I treat mycosis fungoides and Sézary syndrome | Q34998601 | ||
| Molecular cytogenetic characterization of Sézary syndrome | Q35056476 | ||
| Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies | Q35065024 | ||
| Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma | Q35079273 | ||
| Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. | Q35235267 | ||
| Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients | Q35567170 | ||
| Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. | Q35586076 | ||
| Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma | Q35612029 | ||
| The treatment of cutaneous T-cell lymphoma with photopheresis | Q35612038 | ||
| Topical and systemic retinoid therapy for cutaneous T-cell lymphoma | Q35622824 | ||
| Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma | Q35669880 | ||
| Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression | Q35742964 | ||
| Clinicopathological spectrum of mycosis fungoides | Q35804408 | ||
| Discordant expression of antigens between intraepidermal and intradermal T cells in mycosis fungoides | Q35812147 | ||
| Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study | Q35818912 | ||
| Interleukin-7 is a growth factor for Sézary lymphoma cells | Q35822493 | ||
| Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study | Q35827808 | ||
| Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome | Q72354154 | ||
| Combination chemotherapy in the tumour stage of mycosis fungoides with cyclophosphamide, vincristine, vp-16, adriamycin and prednisolone (cop, chop, cavop): a report from the Scandinavian mycosis fungoides study group | Q72628181 | ||
| Induction of nuclear contour irregularity during T-cell activation via the T-cell receptor/CD3 complex and CD2 antigens in the presence of phorbol esters | Q72666167 | ||
| Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome | Q72729394 | ||
| Diagnostic Criteria in Sézary's Syndrome: A Multiparameter Study of Peripheral Blood Lymphocytes in 32 Patients with Erythroderma | Q72797631 | ||
| Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma | Q72813178 | ||
| The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype | Q72880108 | ||
| Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma | Q73042497 | ||
| Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells | Q73069370 | ||
| Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin | Q73294418 | ||
| Sezary lineage cells can be induced to proliferate via CD28-mediated costimulation | Q73326156 | ||
| Increased interleukin 5 production in eosinophilic Sézary syndrome: regulation by interferon alfa and interleukin 12 | Q73372085 | ||
| Expression of apoptosis markers on peripheral blood lymphocytes from patients with cutaneous T-cell lymphoma during extracorporeal photochemotherapy | Q73372093 | ||
| Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma | Q73396460 | ||
| Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma | Q73468261 | ||
| Extracorporeal photopheresis and interferon-α in advanced cutaneous T-cell lymphoma | Q73499034 | ||
| Induction of human tumor-loaded dendritic cells | Q73623155 | ||
| Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients | Q73684481 | ||
| Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression | Q73695727 | ||
| Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN | Q73708485 | ||
| Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma | Q73867868 | ||
| Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab | Q73888073 | ||
| Evaluation of a new paraffin-reactive CD7 T-cell deletion marker and a polymerase chain reaction-based T-cell receptor gene rearrangement assay: implications for diagnosis of mycosis fungoides in community clinical practice | Q74395643 | ||
| Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H | Q74566806 | ||
| Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution | Q74581707 | ||
| Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group | Q74662041 | ||
| The use of anti-T-cell receptor-Vbeta antibodies for the estimation of treatment success and phenotypic characterization of clonal T-cell populations in cutaneous T-cell lymphomas | Q74673987 | ||
| Prognostic factors in Sézary syndrome: a multivariate analysis of clinical, haematological and immunological features | Q77467831 | ||
| Constitutive and interleukin-7/interleukin-15 stimulated DNA binding of Myc, Jun, and novel Myc-like proteins in cutaneous T-cell lymphoma cells | Q77720703 | ||
| Mycosis fungoides: HLA class II associations among Ashkenazi and non-Ashkenazi Jewish patients | Q77779507 | ||
| The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells | Q77869971 | ||
| Lymphocytes treated by extracorporeal photopheresis demonstrate a drop in the Bcl-2/Bax ratio: a possible mechanism involved in extracorporeal-photopheresis-induced apoptosis | Q77893033 | ||
| Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group | Q78224327 | ||
| Sézary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines | Q78385822 | ||
| Sezary's syndrome | Q78832629 | ||
| Sezary syndrome--a malignant reticulemic erythroderma | Q79079984 | ||
| Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma | Q79734221 | ||
| TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of | Q79880342 | ||
| Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma | Q79967580 | ||
| CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sézary syndrome by flow cytometry | Q80152396 | ||
| Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas | Q80155795 | ||
| Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome | Q80216575 | ||
| Transimmunization for cutaneous T cell lymphoma: a Phase I study | Q80243086 | ||
| Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas | Q80292668 | ||
| Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sézary syndrome: circumvention by hexameric soluble CD40L | Q80464383 | ||
| Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma | Q35849529 | ||
| Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy | Q35876581 | ||
| Deoxycoformycin in the treatment of mature T-cell leukaemias | Q35993316 | ||
| Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1 | Q36017473 | ||
| Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin | Q36023863 | ||
| Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. | Q36026719 | ||
| Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome | Q36059635 | ||
| Cutting Edge: Resident Memory CD8 T Cells Express High-Affinity TCRs | Q36119414 | ||
| Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines | Q36239779 | ||
| Hair follicle-derived IL-7 and IL-15 mediate skin-resident memory T cell homeostasis and lymphoma. | Q36258039 | ||
| Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. | Q36349776 | ||
| Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy". | Q36362764 | ||
| CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin | Q36370073 | ||
| Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma | Q36370759 | ||
| EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. | Q36436109 | ||
| Extracorporeal photopheresis: a focus on apoptosis and cytokines | Q36517592 | ||
| Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion | Q36553825 | ||
| P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228 | Q36621938 | ||
| Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma | Q36726860 | ||
| Incidence of TCR and TCL1 gene translocations and isochromosome 7q in peripheral T-cell lymphomas using fluorescence in situ hybridization. | Q36762171 | ||
| MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor | Q36850845 | ||
| Cutaneous T-cell lymphoid dyscrasia: a unifying term for idiopathic chronic dermatoses with persistent T-cell clones | Q36885741 | ||
| Environmental risk factors for mycosis fungoides | Q36886924 | ||
| Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes. | Q36982497 | ||
| Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma | Q37051049 | ||
| Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas | Q37130122 | ||
| Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach | Q37146595 | ||
| Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases | Q37201934 | ||
| Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma | Q37237464 | ||
| B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. | Q37348263 | ||
| Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. | Q37373035 | ||
| Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project | Q37384289 | ||
| Pralatrexate, a new hope for aggressive T-cell lymphomas? | Q37452226 | ||
| Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases | Q42171092 | ||
| The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin. | Q42259563 | ||
| Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa | Q42471736 | ||
| Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin | Q42522243 | ||
| Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome | Q42633099 | ||
| Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. | Q42882402 | ||
| Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma | Q42942114 | ||
| Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma | Q43059183 | ||
| Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. | Q43249154 | ||
| Aberrant Cytokine Production By Sezary Syndrome Patients: Cytokine Secretion Pattern Resembles Murine Th2 Cells | Q43434803 | ||
| Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays | Q43507727 | ||
| Morphologic and functional properties of the atypical T lymphocytes of the Sezary syndrome. | Q43521060 | ||
| Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results | Q43594172 | ||
| A case-control study of possible causative factors in mycosis fungoides | Q43627104 | ||
| Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. | Q43990098 | ||
| Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series | Q44210371 | ||
| Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative Group | Q44373542 | ||
| Septicemic complications of the cutaneous T-cell lymphomas | Q44541983 | ||
| Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series | Q44723870 | ||
| Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H). | Q44763724 | ||
| Management of refractory early-stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy | Q44779593 | ||
| Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides | Q44790858 | ||
| Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation | Q44827099 | ||
| A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas | Q44834795 | ||
| Histologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system | Q45008356 | ||
| Cytogenetic, cytophotometric, and ultrastructural study of large cerebriform cells of the Sézary syndrome and description of a small-cell variant | Q45233042 | ||
| Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. | Q45886829 | ||
| Low-dose methotrexate for the Sézary syndrome. | Q45946736 | ||
| Bexarotene therapy for mycosis fungoides and Sézary syndrome. | Q46119707 | ||
| Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells | Q46124722 | ||
| Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome | Q46148002 | ||
| Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma | Q46175116 | ||
| Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome | Q46185753 | ||
| Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma | Q46207594 | ||
| Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation | Q46434131 | ||
| T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides | Q46508858 | ||
| Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome | Q46535550 | ||
| Infections Complicating Mycosis Fungoides and Sézary Syndrome | Q46649604 | ||
| Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients | Q46744850 | ||
| Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma | Q46970940 | ||
| Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). | Q46988409 | ||
| Clonal T-cell populations and increased risk for cytotoxic T-cell lymphomas in B-CLL patients: clinicopathologic observations and molecular analysis | Q47272487 | ||
| In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. | Q47609542 | ||
| Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis | Q47725371 | ||
| CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome. | Q47758296 | ||
| Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma | Q47800148 | ||
| Flow cytometric assessment of TCR-Vbeta expression in the evaluation of peripheral blood involvement by T-cell lymphoproliferative disorders: a comparison with conventional T-cell immunophenotyping and molecular genetic techniques | Q47947888 | ||
| Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. | Q50477276 | ||
| Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. | Q51103802 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 151-165 | |
| P577 | publication date | 2015-11-26 | |
| P1433 | published in | American Journal of Hematology | Q4744246 |
| P1476 | title | Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management | |
| P478 | volume | 91 |
| Q51484852 | A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome. |
| Q47836540 | AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair |
| Q28074716 | Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies |
| Q26740306 | An overview of cutaneous T cell lymphomas |
| Q92652614 | Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL |
| Q47610009 | Antiproliferative effects of TSA, PXD‑101 and MS‑275 in A2780 and MCF7 cells: Acetylated histone H4 and acetylated tubulin as markers for HDACi potency and selectivity |
| Q64108518 | CAR-Based Approaches to Cutaneous T-Cell Lymphoma |
| Q64109981 | CD4/CD8 Double-negative Mycosis Fungoides: A Case Report and Literature Review |
| Q89907787 | Cost of early-stage mycosis fungoides treatments in Spain |
| Q97524779 | Cutaneous T-cell lymphoma in the setting of anti-tumor necrosis factor and immunomodulator therapy: A case report and literature review |
| Q90070199 | Cutaneous lymphomas : Clinical presentation - diagnosis - treatment |
| Q91993440 | Cytotoxic impact of a perillyl alcohol-temozolomide conjugate, NEO212, on cutaneous T-cell lymphoma in vitro |
| Q47383611 | Inhibition of bcl-2 and cox-2 Protein Expression after Local Application of a New Carmustine-Loaded Clinoptilolite-Based Delivery System in a Chemically Induced Skin Cancer Model in Mice. |
| Q90745231 | Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma |
| Q38892071 | Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. |
| Q97886100 | Long-Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T-Cell Lymphoma; Results From a Single Institution Analysis |
| Q57117878 | Long-term complete remission of early hematological relapse after discontinuation of immunosuppressants following allogeneic transplantation for Sezary syndrome |
| Q37723390 | Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover |
| Q64041638 | MicroRNAs and Long Non-coding RNAs in Genetic Diseases |
| Q51803389 | Monoclonal antibodies against cutaneous T-cell lymphomas. |
| Q53682760 | Multi-kinase inhibitor with anti-p38γ activity in cutaneous T cell lymphoma. |
| Q37542591 | Mycosis Fungoides of the Oral Cavity: Fungating Tumor Successfully Treated with Electron Beam Radiation and Maintenance Bexarotene |
| Q98613057 | Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) epidemiology and treatment pathway in Spain: new insights for an accurate description |
| Q99237825 | Natural Products Impacting DNA Methyltransferases and Histone Deacetylases |
| Q52559876 | Oral Mycosis Fungoides: A Report of Three Cases and Review of the Literature. |
| Q63384386 | Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models |
| Q47122404 | Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas. |
| Q58712956 | Single-cell heterogeneity in Sézary syndrome |
| Q50101634 | Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B Cell Lymphoma and Acute Myeloid Leukemia. |
| Q30244553 | T-cell lymphomas, a challenging disease: types, treatments, and future. |
| Q33716514 | Unique Presentation of Leukemic Cutaneous CD3/TCR- Phenotype T-Cell Lymphoma with Complete Remission after Allogeneic Stem Cell Transplantation. |
| Q88713922 | [Role of stem cell transplantation in treatment of primary cutaneous T‑cell lymphoma] |
Search more.